WIP1 Antibody (Rabbit mAb) [J2N2] Datasheet

Biological Description

Specificity	WIP1 Antibody (Rabbit mAb) [J2N2] detects endogenous levels of total WIP1 protein.
Background	PPM1D, also known as wild‑type p53‑induced phosphatase 1 (WIP1), is a nuclear serine/threonine phosphatase of the PP2C family that is transcriptionally induced by p53 after genotoxic stress and acts as a homeostatic regulator of the DNA damage response by dephosphorylating multiple substrates of ATM and ATR kinases. The protein contains a conserved PP2C catalytic domain and regulatory regions that allow selective recognition of phospho‑Ser/Thr motifs on key checkpoint and stress signaling proteins, enabling WIP1 to function as a “reset” enzyme that terminates checkpoint signaling once damage has been addressed. WIP1 directly dephosphorylates p53 on residues targeted by ATM/ATR, reduces p53 transcriptional activity and forms a negative feedback loop in which p53 induces PPM1D expression and the resulting phosphatase attenuates p53‑dependent cell-cycle arrest and apoptosis, restoring proliferative capacity after DNA repair. The phosphatase also dephosphorylates and inactivates several other tumor suppressors and checkpoint components, including ATM, Chk1, Chk2, γH2AX and p38 MAPK; in the case of Chk2, ATM phosphorylates Thr68 to promote Chk2 dimerization and activation, and WIP1 binds Chk2 and removes phospho‑Thr68, thereby opposing Chk2 activation and suppressing its contribution to the G2/M DNA damage checkpoint. Through concerted dephosphorylation of these substrates, WIP1 reduces DDR signaling thresholds, maintains cells competent for re‑entry into the cell cycle from G2 phase and modulates senescence, apoptosis and autophagy decisions under stress. Regulation of WIP1 itself occurs at multiple levels: p53 drives its transcription, microRNAs such as miR‑16 limit WIP1 expression early in DDR to prevent premature checkpoint termination, and APC/C–Cdc20‑mediated ubiquitin–proteasome degradation lowers WIP1 levels during mitosis, a state in which DNA damage largely remains unrepaired and increased DDR sensitivity in the following G1 phase is beneficial for repair. Oncogenic roles for PPM1D arise when this finely tuned balance is disrupted; the gene is amplified and overexpressed in several human cancers, including breast and ovarian carcinomas, and WIP1 cooperates with classic oncogenes in fibroblast transformation assays, consistent with its capacity to suppress p53, ATM, p16INK4a and ARF pathways and to weaken stress-induced barriers to proliferation. Gain‑of‑function truncating mutations in PPM1D have been identified in hematopoietic and solid tumors and confer enhanced phosphatase activity or stability, impair p53‑mediated checkpoints after DNA damage and predispose cells to tumorigenesis, while Ppm1d‑null mice show resistance to tumor development, supporting a causal role for WIP1 dysregulation in cancer. WIP1 is also expressed in hematopoietic progenitors, lymphoid and myeloid cells, where it influences differentiation and immune function, and its loss leads to immunodeficiency and pro‑inflammatory phenotypes, reflecting its broader role in stress response, NF‑κB and mTOR pathway modulation and tissue homeostasis.

Specificity

WIP1 Antibody (Rabbit mAb) [J2N2] detects endogenous levels of total WIP1 protein.

Background

PPM1D, also known as wild‑type p53‑induced phosphatase 1 (WIP1), is a nuclear serine/threonine phosphatase of the PP2C family that is transcriptionally induced by p53 after genotoxic stress and acts as a homeostatic regulator of the DNA damage response by dephosphorylating multiple substrates of ATM and ATR kinases. The protein contains a conserved PP2C catalytic domain and regulatory regions that allow selective recognition of phospho‑Ser/Thr motifs on key checkpoint and stress signaling proteins, enabling WIP1 to function as a “reset” enzyme that terminates checkpoint signaling once damage has been addressed. WIP1 directly dephosphorylates p53 on residues targeted by ATM/ATR, reduces p53 transcriptional activity and forms a negative feedback loop in which p53 induces PPM1D expression and the resulting phosphatase attenuates p53‑dependent cell-cycle arrest and apoptosis, restoring proliferative capacity after DNA repair. The phosphatase also dephosphorylates and inactivates several other tumor suppressors and checkpoint components, including ATM, Chk1, Chk2, γH2AX and p38 MAPK; in the case of Chk2, ATM phosphorylates Thr68 to promote Chk2 dimerization and activation, and WIP1 binds Chk2 and removes phospho‑Thr68, thereby opposing Chk2 activation and suppressing its contribution to the G2/M DNA damage checkpoint. Through concerted dephosphorylation of these substrates, WIP1 reduces DDR signaling thresholds, maintains cells competent for re‑entry into the cell cycle from G2 phase and modulates senescence, apoptosis and autophagy decisions under stress. Regulation of WIP1 itself occurs at multiple levels: p53 drives its transcription, microRNAs such as miR‑16 limit WIP1 expression early in DDR to prevent premature checkpoint termination, and APC/C–Cdc20‑mediated ubiquitin–proteasome degradation lowers WIP1 levels during mitosis, a state in which DNA damage largely remains unrepaired and increased DDR sensitivity in the following G1 phase is beneficial for repair. Oncogenic roles for PPM1D arise when this finely tuned balance is disrupted; the gene is amplified and overexpressed in several human cancers, including breast and ovarian carcinomas, and WIP1 cooperates with classic oncogenes in fibroblast transformation assays, consistent with its capacity to suppress p53, ATM, p16INK4a and ARF pathways and to weaken stress-induced barriers to proliferation. Gain‑of‑function truncating mutations in PPM1D have been identified in hematopoietic and solid tumors and confer enhanced phosphatase activity or stability, impair p53‑mediated checkpoints after DNA damage and predispose cells to tumorigenesis, while Ppm1d‑null mice show resistance to tumor development, supporting a causal role for WIP1 dysregulation in cancer. WIP1 is also expressed in hematopoietic progenitors, lymphoid and myeloid cells, where it influences differentiation and immune function, and its loss leads to immunodeficiency and pro‑inflammatory phenotypes, reflecting its broader role in stress response, NF‑κB and mTOR pathway modulation and tissue homeostasis.

Usage Information

Application

WB, IF, FCM

Dilution

WB	IF	FCM
1:1000	1:50	1:500

Reactivity

Mouse, Rat, Human

Source

Rabbit Monoclonal Antibody

MW

67 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/18265945/
https://pubmed.ncbi.nlm.nih.gov/16936775/

WIP1 Antibody (Rabbit mAb) [J2N2]

Biological Description

Usage Information

References

Application Data